Cevimeline hydrochloride hemihydrate (SNK-508; FKS-508; AF-102B; SNI-2011; trade name Evoxac), the hydrochloride salt and hemihydrated form of Cevimeline, is a parasympathomimetic and muscarinic receptor agonist that was approved for the treatment of dry mouth and Sjogren's syndrome, as well as Xerostomia symptoms.